Department of Error (DOI:10.1016/S0140-6736(07)60236-0);Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial

Lancet

Volumn 369, Issue 9560, 2007, Pages 491-498

  Zongo, Issaka ^a   Dorsey, Grant ^b   Rouamba, Noel ^a   Tinto, Halidou ^a   Dokomajilar, Christian ^b   Guiguemde, Robert T ^c   Rosenthal, Philip J ^b   Ouedraogo, Jean Bosco ^a  

^a Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRE MURAZ   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; FANSIDAR; HEMOGLOBIN; PARACETAMOL; QUININE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BURKINA FASO; CHILD; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITEMIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SIDE EFFECT; TABLET; TREATMENT OUTCOME; VOMITING; WEAKNESS;

EID: 33846837894     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60408-5     Document Type: Erratum

References (38)

1. Wongsrichanalai C., Pickard A., Wernsdorfer W., and Meshnick S. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 (2002) 209-218
2. Guerin P., Olliaro P., Nosten F., et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2 (2002) 564-573
3. Greenwood B., Bojang K., Whitty C., and Targett G. Malaria. Lancet 365 (2005) 1487-1498
4. World Health Organization. Global Antimalarial Drug Policies database - AFRO. Antimalarial treatment policies for P falciparum and P vivax by country in WHO Africa region. http://www.who.int/malaria/amdp/amdp_afro.htm (accessed May 11, 2006)
5. Snow R., Eckert E., and Teklehaimanot A. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol 19 (2003) 363-369
6. Mockenhaupt F., Ehrhardt S., Dzisi S., et al. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10 (2005) 512-520
7. Zongo I., Dorsey G., Rouamba N., et al. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg 73 (2005) 826-832
8. Yeka A., Banek K., Bakyaita N., et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2 (2005) 190
9. Plowe C., Cortese J., Djimde A., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176 (1997) 1590-1596
10. Duraisingh M., Drakeley C., Muller O., et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology 114 (1997) 205-211
11. Ochong E., van den Broek I., Keus K., and Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 69 (2003) 184-187
12. Holmgren G., Gil J., Ferreira P., Veiga M., Obonyo C., and Bjorkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol 6 (2005) 309-314
13. Sidhu A., Valderramos S., and Fidock D. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 57 (2005) 913-926
14. Mutabingwa T., Anthony D., Heller A., et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 (2005) 1474-1480
15. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (2003), World Health Organization, Geneva
16. WHO/UNICEF. Strategy for Integrated Management of Childhood Illness (IMCI); information package (1999), World Health Organization, Geneva
17. Staedke S., Mpimbaza A., Kamya M., Nzarubara B., Dorsey G., and Rosenthal P. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 364 (2004) 1950-1957
18. Plowe C., Djimde A., Bouare M., Doumbo O., and Wellems T. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52 (1995) 565-568
19. Greenhouse B., Myrick A., Dokomajilar C., et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 75 (2006) 836-842
20. Djimde A., Doumbo O., Steketee R., and Plowe C. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358 (2001) 890-891
21. Kyabayinze D., Cattamanchi A., Kamya M., Rosenthal P., and Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 69 (2003) 247-252
22. Djimde A., Doumbo O., Cortese J., et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344 (2001) 257-263
23. Sisowath C., Stromberg J., Martensson A., et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191 (2005) 1014-1017
24. Dokomajilar C., Nsobya S., Greenhouse B., Rosenthal P., and Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 50 (2006) 1893-1895
25. Falade C., Makanga M., Premji Z., Ortmann C., Stockmeyer M., and de Palacios P. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99 (2005) 459-467
26. Jima D., Tesfaye G., Medhin A., Kebede A., Argaw D., and Babaniyi O. Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 82 (2005) 387-390
27. Koram K., Abuaku B., Duah N., and Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop 95 (2005) 194-203
28. Bukirwa H., Yeka A., Kamya M., et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clinical Trials 1 (2006) 7
29. Staedke S., Kamya M., Dorsey G., et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358 (2001) 368-374
30. Schellenberg D., Kahigwa E., Drakeley C., et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67 (2002) 17-23
31. Dorsey G., Njama D., Kamya M., et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360 (2002) 2031-2038
32. Rwagacondo C., Niyitegeka F., Sarushi J., et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg 68 (2003) 743-747
33. Sowunmi A. A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Ann Trop Med Parasitol 96 (2002) 227-238
34. Price R., Cassar C., Brockman A., et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 43 (1999) 2943-2949
35. Schellenberg D., Menendez C., Aponte J., et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365 (2005) 1481-1483
36. Dorsey G., Dokomajilar C., Kiggundu M., Staedke S., Kamya M., and Rosenthal P. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg 71 (2004) 758-763
37. Marks F., Evans J., Meyer C., et al. High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrob Agents Chemother 49 (2005) 1101-1105
38. Phillips-Howard P., and West L. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 83 (1990) 82-85